CMG-002

N/A

Report date: 2025/01/26 19:05:15
NME

Base Information

Drug NameCMG-002
Drug Alias Namedual PI3K/mTOR inhibitor (CMG Pharmaceutical)ovarian cancer therapy (CMG Pharmaceutical)CMG-002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsPI3-kinase class I inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCmg Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCmg Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A